SPY366.02+3.96 1.09%
DIA298.44+1.82 0.61%
IXIC12,355.11+156.37 1.28%

Agile Therapeutics Q3 EPS $(0.18), Inline; Reports $71.9M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.08) per share from the same period last year.

· 11/12/2020 16:14
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.08) per share from the same period last year.